Javier A Cepeda1, Ksenia Eritsyan2, Peter Vickerman3, Alexandra Lyubimova4, Marina Shegay5, Veronika Odinokova4, Leo Beletsky6, Annick Borquez7, Matthew Hickman3, Chris Beyrer8, Natasha K Martin9. 1. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA. Electronic address: jacepeda@ucsd.edu. 2. NGO Stellit, Saint Petersburg, Russia; Department of Sociology, National Research University Higher School of Economics, Saint Petersburg, Russia. 3. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 4. NGO Stellit, Saint Petersburg, Russia. 5. Russian Health Care Foundation, Moscow, Russia. 6. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; School of Law and Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. 7. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA. 8. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 9. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Abstract
BACKGROUND: Most new HIV infections among people who inject drugs (PWID) in eastern Europe and central Asia occur in Russia, where PWID have a high risk of overdose. In Russia, use of opioid agonist therapy (OAT) is prohibited, and coverage of needle and syringe programmes (NSPs) and antiretroviral therapy (ART) is poor. We aimed to assess the effects that scaling up harm reduction (ie, use of OAT and coverage of NSPs) and use of ART might have on HIV incidence and the frequency of fatal overdoses among PWID in two cities in the Ural Federal District and Siberian Federal District, where the prevalence of HIV is high or increasing in PWID. METHODS: In this modelling study, we developed a dynamic deterministic model that simulated transmission of HIV through injection drug use and sex among PWID. We calibrated this model to HIV prevalence data among PWID in two Russian cities: Omsk (which has high but increasing prevalence of HIV among PWID) and Ekaterinburg (which has very high but stable prevalence of HIV). The source data were from research studies supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria and US Centers for Disease Control and Prevention and surveillance studies from WHO and regional AIDS centres. We modelled the effects of no intervention scale-up (no use of harm reduction measures and 30% of HIV-positive PWID receiving ART) versus combinations of scaling up of OAT, receipt of high coverage of NSPs, and use of ART on the incidence of HIV infections, mortality from HIV, and the frequency of fatal overdoses from 2018 to 2028. FINDINGS: Without intervention, HIV prevalence among PWID in Omsk could increase from 30% in 2018 to 36% (2·5-97·5 percentile interval 22-52) in 2028 and remain high in Ekaterinburg, estimated at 60% (57-67) in 2028. Scaling up OAT to 50% coverage for a duration of 2 years could prevent 35% of HIV infections and 19% of deaths associated with HIV in Omsk and 20% (11-29) of HIV infections and 10% (4-14) of deaths associated with HIV in Ekaterinburg. Further, this scaling up could prevent 33% of overdose deaths over the next 10 years. Scaling up of NSPs and OAT to 50% coverage and tripling recruitment to ART (reaching about 65% of HIV-positive PWID) could prevent 58% (46-69) of HIV infections and 45% (36-54) of deaths associated with HIV in Omsk and 38% (26-50) of HIV infections and 32% (23-41) of deaths associated with HIV in Ekaterinburg by 2028. INTERPRETATION: Legalisation of OAT and increased use of ART and NSPs for PWID are urgently needed to prevent HIV and fatal overdose among PWID in Russia. FUNDING: National Institutes of Health and Elton John AIDS Foundation.
BACKGROUND: Most new HIV infections among people who inject drugs (PWID) in eastern Europe and central Asia occur in Russia, where PWID have a high risk of overdose. In Russia, use of opioid agonist therapy (OAT) is prohibited, and coverage of needle and syringe programmes (NSPs) and antiretroviral therapy (ART) is poor. We aimed to assess the effects that scaling up harm reduction (ie, use of OAT and coverage of NSPs) and use of ART might have on HIV incidence and the frequency of fatal overdoses among PWID in two cities in the Ural Federal District and Siberian Federal District, where the prevalence of HIV is high or increasing in PWID. METHODS: In this modelling study, we developed a dynamic deterministic model that simulated transmission of HIV through injection drug use and sex among PWID. We calibrated this model to HIV prevalence data among PWID in two Russian cities: Omsk (which has high but increasing prevalence of HIV among PWID) and Ekaterinburg (which has very high but stable prevalence of HIV). The source data were from research studies supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria and US Centers for Disease Control and Prevention and surveillance studies from WHO and regional AIDS centres. We modelled the effects of no intervention scale-up (no use of harm reduction measures and 30% of HIV-positive PWID receiving ART) versus combinations of scaling up of OAT, receipt of high coverage of NSPs, and use of ART on the incidence of HIV infections, mortality from HIV, and the frequency of fatal overdoses from 2018 to 2028. FINDINGS: Without intervention, HIV prevalence among PWID in Omsk could increase from 30% in 2018 to 36% (2·5-97·5 percentile interval 22-52) in 2028 and remain high in Ekaterinburg, estimated at 60% (57-67) in 2028. Scaling up OAT to 50% coverage for a duration of 2 years could prevent 35% of HIV infections and 19% of deaths associated with HIV in Omsk and 20% (11-29) of HIV infections and 10% (4-14) of deaths associated with HIV in Ekaterinburg. Further, this scaling up could prevent 33% of overdose deaths over the next 10 years. Scaling up of NSPs and OAT to 50% coverage and tripling recruitment to ART (reaching about 65% of HIV-positive PWID) could prevent 58% (46-69) of HIV infections and 45% (36-54) of deaths associated with HIV in Omsk and 38% (26-50) of HIV infections and 32% (23-41) of deaths associated with HIV in Ekaterinburg by 2028. INTERPRETATION: Legalisation of OAT and increased use of ART and NSPs for PWID are urgently needed to prevent HIV and fatal overdose among PWID in Russia. FUNDING: National Institutes of Health and Elton John AIDS Foundation.
Authors: Bradley M Mathers; Louisa Degenhardt; Hammad Ali; Lucas Wiessing; Matthew Hickman; Richard P Mattick; Bronwyn Myers; Atul Ambekar; Steffanie A Strathdee Journal: Lancet Date: 2010-02-26 Impact factor: 79.321
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Ksenia Eritsyan; Robert Heimer; Russell Barbour; Veronika Odinokova; Edward White; Maia M Rusakova; Tatiana T Smolskaya; Olga S Levina Journal: BMJ Open Date: 2013-06-20 Impact factor: 2.692
Authors: Esther J Aspinall; Dhanya Nambiar; David J Goldberg; Matthew Hickman; Amanda Weir; Eva Van Velzen; Norah Palmateer; Joseph S Doyle; Margaret E Hellard; Sharon J Hutchinson Journal: Int J Epidemiol Date: 2013-12-27 Impact factor: 7.196
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Sarah Larney; Amy Peacock; Janni Leung; Samantha Colledge; Matthew Hickman; Peter Vickerman; Jason Grebely; Kostyantyn V Dumchev; Paul Griffiths; Lindsey Hines; Evan B Cunningham; Richard P Mattick; Michael Lynskey; John Marsden; John Strang; Louisa Degenhardt Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Zoe Ward; Jack Stone; Chrissy Bishop; Viktor Ivakin; Ksenia Eritsyan; Anna Deryabina; Andrea Low; Javier Cepeda; Sherrie L Kelly; Robert Heimer; Robert Cook; Frederick L Altice; Taylor Litz; Assel Terlikbayeva; Nabila El-Bassel; Denis Havarkov; Alena Fisenka; Anelia Boshnakova; Andrey Klepikov; Tetiana Saliuk; Tetiana Deshko; Peter Vickerman Journal: Lancet HIV Date: 2021-12-09 Impact factor: 12.767
Authors: Magdalena Cerdá; Mohammad S Jalali; Ava D Hamilton; Catherine DiGennaro; Ayaz Hyder; Julian Santaella-Tenorio; Navdep Kaur; Christina Wang; Katherine M Keyes Journal: Epidemiol Rev Date: 2022-01-14 Impact factor: 6.222
Authors: Anh T Vo; Christopher Magana; Matthew Hickman; Annick Borquez; Leo Beletsky; Natasha K Martin; Javier A Cepeda Journal: Int J Drug Policy Date: 2021-08-11
Authors: Jack Stone; Louisa Degenhardt; Jason Grebely; Sarah Larney; Frederick L Altice; Pavlo Smyrnov; Afarin Rahimi-Movaghar; Maryam Alavi; April M Young; Jennifer R Havens; William C Miller; Matthew Hickman; Peter Vickerman Journal: Lancet Psychiatry Date: 2021-02-25 Impact factor: 27.083
Authors: Javier A Cepeda; Annick Bórquez; Christopher Magana; Anh Vo; Claudia Rafful; Gudelia Rangel; María E Medina-Mora; Steffanie Strathdee; Natasha K Martin Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez Journal: Addiction Date: 2021-12-04 Impact factor: 7.256